Veterinary Contract Manufacturing & Research Market

The veterinary contract manufacturing & research market is projected to reach USD 9.24 billion by 2031 from USD 6.38 billion in 2026, growing at a CAGR of 7.7% during the forecast period.

The growth of the global veterinary contract manufacturing & research market is driven by the increasing outsourcing of drug development and production, as animal health companies seek to reduce R&D costs, shorten timelines, and gain access to specialized expertise. The rising prevalence of chronic, infectious, and zoonotic diseases in both companion and livestock animals is speeding up the development of new pharmaceuticals, biologics, and vaccines, thereby increasing demand for contract services. The move toward precision veterinary medicine, including genetic testing and targeted therapies, along with the use of non-invasive diagnostics, digital monitoring tools, and data-driven decision-making, is broadening the scope of outsourced research. The integration of advanced technologies, including AI, machine learning, automation, and high-throughput screening, is enhancing efficiency in drug discovery, toxicology, and clinical studies. Growing regulatory complexity, increasing ownership of companion animals, intensification of livestock production, rising private investments, and expanding veterinary research collaborations across regions, especially in emerging markets, are further supporting the robust expansion of the veterinary contract manufacturing & research market.

To know about the assumptions considered for the study download the pdf brochure

The prominent players in the veterinary CDMO market are Aenova Group (Germany), Argenta Holdco Limited (UK), Fareva (France), Vetio (US), TriRx Pharmaceutical Services (US), among others. In contrast, prominent players in the veterinary CRO market are Labcorp (US), Eurofins Scientific (Luxembourg), Charles River Laboratories (US), knoell Germany GmbH (Germany), Evotec (Germany), among others. These companies have implemented a range of growth strategies, including both organic and inorganic approaches, such as introducing new services, forming strategic partnerships, and expanding into emerging markets. These initiatives aim to enhance their market share and diversify their portfolios.

In December 2024, Clinglobal (US) announced the launch of a new brand within the Group: Clinaxel. This brand reinforces Clinglobal’s dedication to delivering high-quality field clinical trials and regulatory services across North America, Europe, and Africa.

In October 2024, Argenta Holdco Limited (UK) announced the completion of the carve-out acquisition of TriRx Pharmaceuticals’ manufacturing site in Shawnee, Kansas. The Shawnee facility will now operate under Argenta as a key end-to-end CDMO hub, offering sterile fill-finish, non-sterile liquids and pastes, and oral solid dose capabilities.

Veterinary CDMO

Aenova Group, a global CDMO headquartered in Starnberg, Germany, provides end-to-end development, manufacturing, and packaging services across pharmaceutical, healthcare, and veterinary-health markets, covering a broad range of dosage forms including solids, semi-solids, and sterile injectables. Operating through four segments—Conventionals, On-Patent Originator Products, Specialty Platforms, and Development Services—the company manages everything from large-scale production of mature and OTC products to patented drugs, high-potency and complex formulations, and full formulation-to-commercialization support. Veterinary CDMO activities fall under the Conventionals segment, where Aenova delivers comprehensive services for both companion and farm animal products, including anti-infectives, parasiticides, hormones, supplements, biologics, and related packaging and logistics. The company operates 14 manufacturing and development sites across Germany, Switzerland, Italy, Ireland, Romania, and the US, with seven approved for veterinary use. Notably, its Latina, Italy site serves as a key competence center for animal-health products and sterile technologies.

Fareva is a global CDMO with a strong footprint across Europe, the Americas, and Asia, providing industrial subcontracting services across pharmaceuticals, APIs, cosmetics, household, and industrial products. Its pharmaceutical and API divisions support both human and veterinary markets with comprehensive formulation, analytical, clinical, commercial manufacturing, and packaging capabilities across a diverse range of dosage forms. Fareva’s veterinary CDMO offerings encompass non-sterile liquids, sterile injectables, solid oral products, specialized formulations, and dedicated API production for veterinary drug substance needs, making it a full-service partner for both finished-dose and API manufacturing. Operating more than 40 sites in 14 countries with over 13,000 employees, the company maintains several facilities certified for veterinary medicinal products, including key French sites equipped for the handling of non-sterile liquids, sterile injectables, and high-potency APIs.

Veterinary CRO

Labcorp is a global life-sciences company that delivers integrated clinical laboratory testing, drug development services, and data-driven healthcare solutions, supporting physicians, health systems, biopharmaceutical companies, and government agencies in diagnostics, clinical decision-making, patient management, and therapeutic innovation. It operates through two main segments: Diagnostics Laboratories, which offers routine and specialized tests, including molecular diagnostics, pathology, oncology, genomics, and digital health solutions; and Biopharma Laboratory Services, which provides comprehensive R&D support, such as preclinical studies, safety assessment, bioanalysis, central-lab services, and clinical-trial testing. Veterinary CRO services are delivered through this Biopharma Laboratory Services segment, leveraging Labcorp’s non-clinical and clinical laboratory capabilities, bioanalytical expertise, and global central laboratory infrastructure for animal health developers. With a presence in 100 countries across major global regions, Labcorp operates through subsidiaries such as Labcorp Drug Development (US), Labcorp Europe B.V. (Netherlands), and Labcorp Japan K.K.

Eurofins Scientific is a global leader in life sciences testing, providing analytical and advisory services across food, environmental, pharmaceutical, biotechnology, clinical diagnostics, and consumer product sectors. Organized into three geographic segments: Europe, North America, and the Rest of the World, the company delivers its services through units such as BioPharmaceutical Services, Food and Feed Testing, Clinical Diagnostics, Environment Testing, and Consumer Product Testing. Veterinary contract research is offered primarily through its BioPharmaceutical Services division, which supports the animal-health value chain with bioanalysis, safety and residue testing, contaminant analysis, feed and food-chain studies, and specialized preclinical capabilities, including pharmacokinetic, bioequivalence, residue, and animal-safety studies. Operating in more than 60 countries with over 950 laboratories, Eurofins maintains key veterinary facilities such as its GLP-accredited site in Australia, alongside subsidiaries including Eurofins Animal Health Australia Pty Ltd. and Eurofins Laboratoire Nutrition Animale France SAS.

Market Ranking (CDMO)

The top five companies of the veterinary CDMO market are Argenta Holdco Limited (UK), Aenova Group (Germany), Fareva (France), Vetio (US), and TriRx Pharmaceutical Services (US). Fareva is expanding its role in the veterinary CDMO market through its global network of GMP-approved sites, offering sterile injectables, solid dosage forms, and specialized formulations for animal health manufacturers. Vetio is strengthening its veterinary portfolio by providing development and commercial manufacturing support for animal-health products, including sterile parenterals and complex formulations. Aenova Group continues to advance its veterinary CDMO position with end-to-end development and manufacturing capabilities across multiple certified sites, supporting both companion-animal and livestock medicines. TriRx Pharmaceutical Services is expanding its presence in the veterinary sector by providing comprehensive development, manufacturing, and packaging services for a diverse range of animal health pharmaceuticals. Argenta Holdco Limited is reinforcing its leadership in animal-health CDMO services by delivering formulation development, analytical testing, and commercial manufacturing tailored specifically to veterinary therapeutics.

Market Ranking (CRO)

The top five companies of the veterinary CRO market are Labcorp (US), Eurofins Scientific (Luxembourg), Charles River Laboratories (US), Knoll Germany GmbH (Germany), and Evotec (Germany). Labcorp is strengthening its veterinary CRO leadership by providing global non-clinical and clinical laboratory services, bioanalysis, and safety studies that support animal-health drug development. Eurofins Scientific is expanding its veterinary CRO capabilities through comprehensive bioanalysis, residue testing, and GLP preclinical studies that accelerate veterinary product safety and efficacy assessment. Charles River Laboratories continues to advance its position in the veterinary CRO market with extensive in vivo safety, toxicology, and preclinical research services for animal-health innovations. Knoell Germany GmbH is enhancing its veterinary CRO role by offering regulatory consulting, study management, and safety assessments that support global approvals for veterinary pharmaceuticals. Evotec is growing its presence in animal-health R&D by providing discovery-to-preclinical services, including screening, biology, and translational research, to advance next-generation veterinary therapeutics.

Related Reports:

Veterinary Contract Manufacturing & Research Market by Service (Discovery, API Development, Regulatory Affairs, Consulting, Packaging & Labeling), Product (API, Fill-Finish, Medical Devices), Animal Type (Companion, Livestock) - Global Forecast to 2031

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com